China Pharma Holdings, Inc. (CPHI) — Analysis Summary
China Pharma Holdings, Inc. (CPHI) has a market cap of $37.45M with year-over-year revenue growth of -8.5%. Net margin stands at -76.9%. The stock trades at a P/E ratio of -8.4.
Key Takeaways
- Revenue changed -8.5% year-over-year
- Net margin of -76.9%
- P/E ratio of -8.4
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, CPHI posted revenue growth of -8.5% and trades at a P/E of -8.4.
China Pharma Holdings, Inc. (CPHI)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -136.3x — earnings do not cover interest payments
Current ratio at 0.26x — severe short-term liquidity risk
Operating margin at -111.8% — severe operating losses
Net margin at -114.3% — losses exceed revenue (possible one-time charges)
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
221
Headquarters
HAINAN PROVINCE, F4
Exchange
XASE
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.